| scholarly article | Q13442814 |
| P50 | author | Matteo Tebaldi | Q38640686 |
| Gianluca Campo | Q38640691 | ||
| Marco Valgimigli | Q44964242 | ||
| P2093 | author name string | Roberto Ferrari | |
| Jlenia Marchesini | |||
| Francesco Bernardi | |||
| Giovanni Parrinello | |||
| Barbara Lunghi | |||
| Paolo Ferraresi | |||
| Matteo Miccoli | |||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| clopidogrel | Q410237 | ||
| P304 | page(s) | 2474-2483 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. | |
| P478 | volume | 57 |
| Q58695080 | A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Prophylactic Effect of Traditional Chinese Medicine Supplementing Qi and Hemostasis Formula on Gastrointestinal Bleeding after Percutaneous Coronary Intervention in Patients at High Risks |
| Q36081188 | A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome |
| Q38221608 | A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users |
| Q34441355 | ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis |
| Q87693837 | ANTARCTIC: platelet function testing to adjust therapy - Authors' reply |
| Q38027576 | Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q37965609 | Antiplatelet therapy in acute coronary syndromes. |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q37902507 | Assessment of oral antithrombotic therapy by platelet function testing |
| Q50862709 | Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. |
| Q37390051 | Bleeding events and maintenance dose of prasugrel: BLESS pilot study. |
| Q35602726 | CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis |
| Q38106616 | Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. |
| Q86202099 | Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor |
| Q93175682 | Clopidogrel Pharmacogenetics |
| Q38640902 | Clopidogrel Response Variability: Review of the Literature and Practical Considerations |
| Q54073059 | Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. |
| Q26829251 | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding |
| Q50854235 | Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. |
| Q92616771 | Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor |
| Q88195979 | Current Concepts in the Clinical Utility of Platelet Reactivity Testing |
| Q49058595 | Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients |
| Q58070771 | Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor |
| Q39025194 | Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? |
| Q42276271 | Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis |
| Q38023512 | Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis |
| Q47792745 | Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. |
| Q37642212 | Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation |
| Q37328353 | Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial |
| Q41250240 | Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention |
| Q37497555 | Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. |
| Q47161058 | Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin. |
| Q50868428 | Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. |
| Q33837665 | Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel |
| Q41826841 | Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting |
| Q33365061 | Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance |
| Q36060147 | Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial |
| Q37680302 | High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction. |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q50956895 | Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. |
| Q36045746 | Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q56525434 | Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction |
| Q93092007 | Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice |
| Q37694929 | Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis |
| Q44986245 | Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease |
| Q93382466 | Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients |
| Q33933475 | Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention |
| Q51713992 | Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. |
| Q46265497 | Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q41069868 | Low On-Treatment Platelet Reactivity Predicts Long-Term Risk of Bleeding After Elective PCI. |
| Q38734885 | Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease |
| Q93379475 | Monitoring platelet function: what have we learned from randomized clinical trials? |
| Q46653236 | Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. |
| Q38780997 | Novel strategies for assessing platelet reactivity |
| Q83506904 | Persistent high on-treatment platelet reactivity in acute coronary syndrome |
| Q26775125 | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls |
| Q53178855 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. |
| Q38199010 | Pharmacogenetics of antiplatelet therapy |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q41574497 | Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. |
| Q92637510 | Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s |
| Q89980169 | Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial |
| Q36216424 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. |
| Q38068348 | Platelet function monitoring and clopidogrel |
| Q34035039 | Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? |
| Q48761160 | Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial |
| Q38094681 | Platelet function testing and tailored antiplatelet therapy |
| Q51746988 | Platelet function testing in contemporary clinical and interventional practice. |
| Q38080466 | Platelet function testing in patients with acute coronary syndrome |
| Q94476029 | Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis |
| Q44587286 | Platelet reactivity after coronary stenting |
| Q38132252 | Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know |
| Q50140654 | Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials |
| Q88546012 | Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis |
| Q35204942 | Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study |
| Q90246710 | Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation |
| Q37972231 | Recent advances in the pharmacogenetics of clopidogrel |
| Q90084142 | Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography |
| Q38258270 | Resistance to antiplatelet drugs: what progress has been made? |
| Q37973457 | Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? |
| Q38048837 | Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors |
| Q39187857 | Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity |
| Q45710775 | St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). |
| Q52903362 | Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. |
| Q40498149 | Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping |
| Q92195567 | Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor |
| Q46389656 | Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory |
| Q92510068 | The Influence of Inflammation on Fibrinogen Turnover and Redistribution of the Hemostatic Balance to a Prothrombotic State in High On-Treatment Platelet Reactivity-Dual Poor Responder (HTPR-DPR) Patients |
| Q38053481 | The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. |
| Q26996594 | The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients |
| Q51063040 | The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. |
| Q37082703 | The new biology: a bridge to clinical cardiology |
| Q26801867 | The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 |
| Q37913976 | The pharmacogenetics of antiplatelet agents: towards personalized therapy? |
| Q36039469 | Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial |
| Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
| Q48182667 | Variability of on-treatment platelet reactivity in patients on clopidogrel |
| Q89689960 | β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease |
Search more.